Files
Download Full Text (852 KB)
Contents
- Despite Initial Setbacks, Researchers Are Focusing on Antiangiogenic Therapy More Than Ever
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Response to Antiangiogenesis Agents
- "Smart Bombs": Targeted Therapies Home in on Increasingly Well-Defined Targets
- House Call: Understanding Angiogenesis
- DiaLog: Gene Therapy for Cancer: Safety First, by Jack Roth, MD, Chair, Department of Thoracic and Cardiovascular Surgery
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Publication Date
2004
Publisher
The University of Texas MD Anderson Cancer Center
City
Houston, Texas
Keywords
Fidler, Isaiah J., 1936-; Folkman, M. Judah; Herbst, Roy; O'Reilly, Michael; Podoloff, Donald A., 1938-; Price, Roger E.; Roth, Jack A.; Andreeff, Michael, 1934-; Marini, Frank, III; Clinical Trials, Phase I as Topic; Vascular Endothelial Growth Factors; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Maintenance Chemotherapy; Neoplasm Metastasis; Magnetic Resonance Imaging; Clinical Trials, Phase II as Topic; Genes, p53; Tumor Suppressor Protein p53; Genetic Therapy; Adenoviridae; Stem Cells; Angiogenesis Inhibitors; Gefitinib; Lung Neoplasms -- secondary; Molecular Targeted Therapy; Angiogenesis Inhibitors; Genetic Therapy -- adverse effects; Viral Proteins.
Disciplines
History of Science, Technology, and Medicine | Oncology
Recommended Citation
O'Suilleabhain, Kate; Matias, Katie Prout; and Roth, Jack MD, "OncoLog, Volume 49, Number 06, June 2004" (2004). OncoLog MD Anderson's Report to Physicians (All issues). 126.
https://openworks.mdanderson.org/oncolog/126
Conditions Governing Access
Open
